Literature DB >> 12849120

The production and use of cells as therapeutic agents in neurodegenerative diseases.

Ole Isacson1.   

Abstract

Although progressive neurodegenerative diseases have very different and highly specific causes, the dysfunction or loss of a vulnerable group of neurons is common to all these disorders and may allow the development of similar therapeutic approaches to the treatment of diseases such as amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. When a disease is diagnosed, the first step is to instigate protective measures to prevent further degeneration. However, most patients are symptom-free until almost all of the vulnerable cells have become dysfunctional or have died. There are known molecular mechanisms and processes in stem cells and progenitor cells that may be of use in the future design and selection of cell-based replacement therapies for neurological diseases. This review provides examples of conceptual and clinical problems that have been encountered in the development of cell-based treatments, and specific criteria for the effective use of cells in the future treatment of neurodegenerative diseases.

Entities:  

Mesh:

Year:  2003        PMID: 12849120     DOI: 10.1016/s1474-4422(03)00437-x

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  22 in total

1.  Conference report--stem cells and neurologic repair: highlights from the annual meeting of the American Society of Neuroscience; November 8-12, 2003; New Orleans, Louisiana.

Authors:  Sara M Mariani
Journal:  MedGenMed       Date:  2004-01-13

2.  The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.

Authors:  Timothy P O'Connor; Ronald G Crystal
Journal:  Trans Am Clin Climatol Assoc       Date:  2004

3.  Ole Isacson: development of new therapies for Parkinson's disease (interview).

Authors:  Ole Isacson
Journal:  J Vis Exp       Date:  2007-04-29       Impact factor: 1.355

Review 4.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

Review 5.  Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients.

Authors:  Oliver Cooper; Arnar Astradsson; Penny Hallett; Harold Robertson; Ivar Mendez; Ole Isacson
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

6.  A tyrosine hydroxylase-yellow fluorescent protein knock-in reporter system labeling dopaminergic neurons reveals potential regulatory role for the first intron of the rodent tyrosine hydroxylase gene.

Authors:  B B Kelly; E Hedlund; C Kim; H Ishiguro; O Isacson; D M Chikaraishi; K-S Kim; G Feng
Journal:  Neuroscience       Date:  2006-07-31       Impact factor: 3.590

7.  Sorting the wheat from the chaff in dopamine neuron-based cell therapies.

Authors:  Ole Isacson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

8.  Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum.

Authors:  Igor Nasonkin; Vasiliki Mahairaki; Leyan Xu; Glen Hatfield; Brian J Cummings; Charles Eberhart; David K Ryugo; Dragan Maric; Eli Bar; Vassilis E Koliatsos
Journal:  Stem Cells       Date:  2009-10       Impact factor: 6.277

9.  Influence of cell preparation and target location on the behavioral recovery after striatal transplantation of fetal dopaminergic neurons in a primate model of Parkinson's disease.

Authors:  D E Redmond; A Vinuela; J H Kordower; O Isacson
Journal:  Neurobiol Dis       Date:  2007-08-28       Impact factor: 5.996

10.  Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro.

Authors:  Sangmi Chung; Byoung-Soo Shin; Michelle Hwang; Thomas Lardaro; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  Stem Cells       Date:  2006-03-16       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.